Form 4: Allogene Therapeutics Director Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Deborah M. Messemer, a director at Allogene Therapeutics, sold 13,313 shares of common stock at an average price of $2.43 per share on February 18, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 18, 2025, Deborah M. Messemer, a director of Allogene Therapeutics, Inc. (ALLO), sold 13,313 shares of common stock.
- The sale was executed at a weighted average price of $2.43 per share, with individual transactions ranging from $2.42 to $2.44.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 30, 2024.
- Following the transaction, Messemer directly owns 144,316 shares of Allogene Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.
Industry Context
Sales by company directors are a normal part of business. It is important to note that the sale was executed under a pre-arranged 10b5-1 trading plan, which is a common practice to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 08/30/2024 | Date the reporting person adopted a Rule 10b5-1 trading plan |
| 02/18/2025 | Date of the transaction (stock sale) |
| 02/20/2025 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.